HST 1021
Alternative Names: HST-1021Latest Information Update: 26 Jun 2024
At a glance
- Originator HotSpot Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 20 Jun 2024 Pharmacodynamics and adverse event data from the preclinical studies in haematological malignancies and solid tumours released by HotSpot Therapeutics
- 11 Dec 2023 Pharmacodynamics data from a preclinical studies in Haematological malignancies released by HotSpot Therapeutics
- 02 Nov 2023 Preclinical trials in Haematological malignancies in USA (unspecified route) before November 2023